← Back to Treatments
🏅 FDA Orphan Designation

ADAKVEO

CRIZANLIZUMAB

Manufacturer: Novartis Pharmaceuticals Corporation

Indicated for:
Sickle cell diseaseOrphan

FDA-Approved Indications (1)

Sickle cell diseaseOrphan Designation

1 INDICATIONS AND USAGE ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. ADAKVEO is a s…

Indications & Usage

1 INDICATIONS AND USAGE ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. ADAKVEO is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.

💙 Support Programs

View all →
ADAKVEO
Novartis
Copay card ↗Apply ↗
ADAKVEO
Novartis Pharmaceuticals Corporation
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.